Robert J. Bertolini

Director, Bristol-Myers Squibb.

Companies

Charles River LaboratoriesBoard member Jan 28, 2011 to May 15, 2024¹
Bristol-Myers SquibbBoard member Feb 23, 2017 to Apr 2, 2021²
Merck & Co.Executive Vice President May 23, 2006 to Nov 4, 2009³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Bristol-Myers Squibb BMY11,397 shares⁴$694.7K at $60.95Jul 31, 2019

As of each latest filing. The line shows shares held over time.

Recent filings

May 13, 2024Granted 394 shares at $228.41 of CIK 1100682⁵
May 13, 2024Granted 559 shares at $228.41 of CIK 1100682⁵
May 15, 2023Granted 468 shares of CIK 1100682⁶
May 15, 2023Granted 664 shares of CIK 1100682⁶
May 11, 2022Granted 405 shares of CIK 1100682⁷
May 11, 2022Granted 575 shares of CIK 1100682⁷
Jul 31, 2019Bought 11,000 shares at $44.72 of Bristol-Myers Squibb⁴

Trade performance

Date	Stock	Trade	Value	Return since	Vs S&P since	Vs S&P, 1 year
Jul 31, 2019	BMY	Buy	$491.9K	+34.5%	−124.9%	+23.6%

Returns are price-only (no dividends), measured from the trade date.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCharles River Laboratories, Board member
2
SEC EDGARBristol-Myers Squibb, Board member
3
SEC EDGARMerck & Co., Executive Vice President
4
SEC EDGARBristol-Myers Squibb shares after the filing of Jul 31, 2019
5
SEC EDGARForm 4 filed May 15, 2024
6
SEC EDGARForm 4 filed May 17, 2023
7
SEC EDGARForm 4 filed May 13, 2022